6533b829fe1ef96bd12899cf
RESEARCH PRODUCT
P-281 JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1 antibody) maintenance therapy vs continuation of first-line chemotherapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction cancer
Wilbur DeborahCuillerot Jean-marieGurtler JayneMoehler MarkusCubillo AntonioBoku NarikazuTaieb JulienDi Bartolomeo MariaZhang JennyXiong Huilingsubject
Oncologymedicine.medical_specialtyLocally advancedGastroenterologyAvelumabAbstracts03 medical and health sciences0302 clinical medicineMaintenance therapyInternal medicinemedicineIn patient030212 general & internal medicinebiologybusiness.industryCancerHematologymedicine.diseaseChemotherapy regimenOncology030220 oncology & carcinogenesisbiology.proteinFirst line chemotherapyAntibodybusinessmedicine.drugyear | journal | country | edition | language |
---|---|---|---|---|
2016-06-01 | Annals of Oncology |